Elsevier

Psychiatry Research

Volume 178, Issue 2, 30 July 2010, Pages 295-298
Psychiatry Research

Preliminary evidence of ethnic divergence in associations of putative genetic variants for methamphetamine dependence

https://doi.org/10.1016/j.psychres.2009.07.019Get rights and content

Abstract

Research into the biological processes that increase susceptibility to methamphetamine dependence has been conducted primarily in Asian populations. Using a case–control design this study's purpose was to explore, among a population of methamphetamine-dependent Caucasians, six putative single nucleotide polymorphisms previously found to be associated with methamphetamine dependence in Asian populations. A total of 193 non-psychotic males (117 methamphetamine-dependent and 76 controls) were genotyped for variants located in six genes (AKT1, ARRB2, BDNF, COMT, GSTP1, OPRM1). Genotypic and allelic frequencies, odds ratios, and 95% confidence intervals were calculated. None of the putative gene associations was significantly replicated in our sample of Caucasian men. Effect size comparisons suggest a trend toward allelic divergence for arrestin beta 2 (ARRB2) and glutathione S-transferase P1 (GSTP1) and allelic convergence for brain-derived neurotrophic factor (BDNF). Results provide preliminary support for further exploration and validation of candidate single nucleotide polymorphisms (SNPs) for methamphetamine (METH) dependence reported among Asian populations across other ethnic/ancestral groups.

Introduction

Methamphetamine (METH) is a powerful illicit psychostimulant that has become increasingly popular throughout North America (Maxwell and Rutkowski, 2008). As a result, initiation of METH use and the progression to abuse and subsequent dependence have received increased attention in both research and clinical settings. However, unlike other substances of abuse (e.g., alcohol, cocaine), efforts to understand the genetic factors that may increase susceptibility to METH dependence have been limited. Twin studies have shown significantly high heritability of stimulant use disorders (Tsuang et al., 1996, Tsuang et al., 1998, Kendler et al., 2003); thus, the search for risk genes underlying these disorders is warranted. Some progress in identifying risk genes for METH dependence has been made, but almost exclusively in Asian populations (for reviews see Barr et al., 2006, Bousman et al., 2009). In these studies, several genes have been implicated across several biological pathways, ranging from dopamine-metabolism and signaling to neuronal survival factors. However, replication of these initial genotypic and allelic associations has not been attempted among non-Asian populations.

It is generally accepted, as a result of efforts by the International Haplotype Mapping Project (HapMap) (International HapMap Consortium, 2005), that genotypic and allelic variations can differ greatly from one ancestral group to the next. In fact, in a recent genome-wide association study of METH dependence (Uhl et al., 2008), it was reported that ethnic allelic divergence is probable. Thus, it is necessary to verify genetic associations not only within but also across populations. Since the completion of the human genome, a large amount of studies have purported gene-disorder associations that have not been replicated in similar and/or different populations. It is this particular propensity toward type-I errors that requires repeated investigations of genetic associations within and across populations. Thus, the purpose of this study was to explore for the first time, to our knowledge, putative single nucleotide polymorphisms (SNPs) for METH dependence in a non-Asian sample. We selected and examined, among a population of METH-dependent Caucasians, six putative SNPs (AKT1, ARRB2, BDNF, COMT, GSTP1, OPRM1) recently found to be associated with METH dependence in Asian populations.

Section snippets

Participants

Participants were 193 nonpsychotic unrelated males (117 METH-dependent and 76 controls) evaluated at the HIV Neurobehavioral Research Center (HNRC) at the University of California, San Diego, as part of a cohort study focused on central nervous system effects of HIV and methamphetamine. The mean age of control (M = 39.6, standard deviation (S.D.) =10.2) and METH-dependent (M = 38.6, S.D. = 8.2) participants were not statistically different (t = 0.73, df = 191, P = 0.42).

Recruitment methods have been

Results

Table 2 displays genotype frequencies of the six SNPs (AKT1, ARRB2, BDNF, COMT, GSTP1, OPRM1) previously implicated in Asian samples. Among controls, each of the selected genotypes was in Hardy–Weinberg equilibrium (HWE) and allele frequencies were similar to those reported by the National Center for Biotechnology Information SNPs Database with the exception of OPRM1 (HWE: χ2 = 7.48, df = 1, P = 0.006). None of the polymorphisms found to be significantly associated with METH dependence among Asian

Discussion

To our knowledge, this study is the first to explore previously reported gene-associations for METH dependence in non-Asian (Caucasian) population and provide evidence that genotypic susceptibility to METH dependence may differ by ethnicity, albeit previous research (Sery et al., 2001) has examined genotypic susceptibility in Caucasian METH users. Among the six putative SNPs previously found to be associated with METH dependence among Asians, we did not statistically replicate any association

Acknowledgments

The authors wish to acknowledge support from the United States National Institutes of Health (grant numbers P01-DA12065 and P30-MH62512) and the contributions of study participants and staff at the HIV Neurobehavioral Research Center (HNRC), San Diego, CA, USA. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, nor the United States Government.

References (16)

  • A.M. Barr et al.

    The need for speed: an update on methamphetamine addiction

    Journal of Psychiatry & Neuroscience JPN

    (2006)
  • Bousman C.A., Glatt S.J., Everall I.P., Tsuang M.T., 2009. Genetic association studies of methamphetamine use...
  • Cheng C.Y., Hong C.J., Yu Y.W., Chen T.J., Wu H.C., Tsai S.J., 2005. Brain-derived neurotrophic factor (Val66Met)...
  • T. Hashimoto et al.

    A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population

    American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The official publication of the International Society of Psychiatric Genetics

    (2005)
  • M. Ikeda et al.

    Positive association of AKT1 haplotype to Japanese methamphetamine use disorder

    The International Journal of Neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)

    (2006)
  • M. Ikeda et al.

    Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia

    Genes, Brain, and Behavior

    (2007)
  • A haplotype map of the human genome

    Nature

    (2005)
  • K.S. Kendler et al.

    Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins

    The American Journal of Psychiatry

    (2003)
There are more references available in the full text version of this article.

Cited by (0)

1

The HNRC Group is affiliated with the University of California, San Diego, the Naval Hospital, San Diego, and the Veterans Affairs San Diego Healthcare System, and includes: Director: Igor Grant, M.D.; Co-Directors: J. Hampton Atkinson, M.D., Ronald J. Ellis, M.D., Ph.D., and J. Allen McCutchan, M.D.; Center Manager: Thomas D. Marcotte, Ph.D.; Business Manager: Melanie Sherman; Naval Hospital San Diego: Braden R. Hale, M.D., M.P.H. (P.I.); Neuromedical Component: Ronald J. Ellis, M.D., Ph.D. (P.I.), J. Allen McCutchan, M.D., Scott Letendre, M.D., Edmund Capparelli, Pharm.D., Rachel Schrier, Ph.D.; Jennifer Marquie-Beck; Terry Alexander, R.N.; Neurobehavioral Component: Robert K. Heaton, Ph.D. (P.I.), Mariana Cherner, Ph.D., Steven Paul Woods, Psy.D., David J. Moore, Ph.D.; Matthew Dawson, Donald Franklin; Neuroimaging Component: Terry Jernigan, Ph.D. (P.I.), Christine Fennema-Notestine, Ph.D., Sarah L. Archibald, M.A., John Hesselink, M.D., Jacopo Annese, Ph.D., Michael J. Taylor, Ph.D., Neurobiology Component: Eliezer Masliah, M.D. (P.I.), Ian Everall, FRCPsych., FRCPath., Ph.D., Cristian Achim, M.D., Ph.D.; Neurovirology Component: Douglas Richman, M.D., (P.I.), David M. Smith, M.D.; International Component: J. Allen McCutchan, M.D., (P.I.); Developmental Component: Ian Everall, FRCPsych., FRCPath., Ph.D. (P.I.), Stuart Lipton, M.D., Ph.D.; Clinical Trials Component: J. Allen McCutchan, M.D., J. Hampton Atkinson, M.D., Ronald J. Ellis, M.D., Ph.D., Scott Letendre, M.D.; Participant Accrual and Retention Unit: J. Hampton Atkinson, M.D. (P.I.), Rodney von Jaeger, M.P.H.; Data Management Unit: Anthony C. Gamst, Ph.D. (P.I.), Clint Cushman (Data Systems Manager), Daniel R. Masys, M.D. (Senior Consultant); Statistics Unit: Ian Abramson, Ph.D. (P.I.), Florin Vaida, Ph.D., Christopher Ake, Ph.D.

View full text